Company news

Capricor Therapeutics, Inc. news in 2026

Capricor Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

November 3, 2026

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

October 5, 2026

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

September 17, 2026

SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline

September 11, 2026

Pomerantz LLP Issues Reminder to Investors in Capricor Therapeutics, Inc. of Class Action Filing - CAPR

August 26, 2026

Capricor Therapeutics, Inc. (CAPR) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 28, 2026 Lead Plaintiff Deadline

August 25, 2026

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

August 24, 2026

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

August 21, 2026

Pomerantz LLP Alerts Shareholders to Investor Suit Against Capricor Therapeutics, Inc. - CAPR

August 17, 2026

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026

Capricor Therapeutics, Inc. (CAPR) Securities Fraud Investigation - Levi & Korsinsky

August 3, 2026

CAPR SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. for Possible Securities Law Violations

August 2, 2026

CAPR Investor Alert: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) for Potential Securities Fraud

August 1, 2026

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

July 30, 2026

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

July 29, 2026

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

July 29, 2026

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

June 26, 2026

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

June 26, 2026

Capricor Therapeutics Expands Commercial Leadership Team

May 28, 2026

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

May 4, 2026

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

April 22, 2026

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 12, 2026

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

March 11, 2026

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

March 9, 2026

Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

March 8, 2026

Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference

February 23, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

February 5, 2026

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data

January 20, 2026

Calls in 2026

Decks in 2026